Atlas Trials

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT01955499 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT01955499
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone Lymphoma
Start date
2013-09-24
Primary completion
2024-11-06
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.